Claritin (Loratadine) Availability: A Provider Briefing for 2026

As allergy seasons continue to intensify and patient inquiries about medication availability increase, it's important for providers and prescribers to have a clear picture of the Claritin (Loratadine) supply landscape. This article provides a concise clinical briefing on the current availability status, prescribing considerations, and tools to help your patients access antihistamine therapy in 2026.

Current Shortage Status and Timeline

As of early 2026, Loratadine is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortage List. There is no formal supply disruption for any Loratadine formulation, including brand-name Claritin products.

Loratadine has historically maintained one of the most stable supply chains among OTC medications. Key factors contributing to this stability include:

• Multiple manufacturers: Dozens of generic manufacturers produce Loratadine tablets, creating significant supply redundancy
• OTC status: Since transitioning to OTC in 2002, Loratadine distribution operates through retail channels with broad availability
• Simple manufacturing: Loratadine is a well-established molecule with straightforward production requirements, reducing the risk of manufacturing disruptions
• Global production: Loratadine is manufactured in facilities worldwide, reducing geographic concentration risk

While no formal shortage exists, providers should be aware that seasonal demand fluctuations can cause temporary stock-outs at individual retail locations during peak allergy periods (March–June, September–November). These are demand-driven, not supply-driven, and typically resolve within days.

Prescribing Implications

For most patients, Loratadine does not require a prescription. However, there are several clinical scenarios where prescribing decisions may be relevant:

OTC Recommendations

When recommending Loratadine as first-line therapy for allergic rhinitis or chronic urticaria, providers should be aware of the following:

• Standard dosing: 10 mg once daily for adults and children ≥6 years; 5 mg once daily for children ages 2–5
• Dose adjustment: 10 mg every other day for patients with hepatic impairment or renal impairment (GFR <30 mL/min)
• No boxed warnings: Loratadine carries no FDA boxed warnings
• Pregnancy Category B: Generally considered safe during pregnancy when clearly needed
• Geriatric use: Preferred over first-generation antihistamines in the Beers Criteria population due to lower anticholinergic burden and reduced sedation risk

When to Consider Prescription Alternatives

If OTC Loratadine provides inadequate symptom control, consider:

• Desloratadine (Clarinex): The active metabolite of Loratadine, available by prescription. May benefit patients with CYP3A4-related drug interaction concerns since it bypasses first-pass metabolism
• Prescription-strength intranasal corticosteroids: Remain the cornerstone of long-term allergic rhinitis management per AAO-HNS guidelines
• Combination therapy: Loratadine plus intranasal corticosteroid for moderate-to-severe allergic rhinitis
• Specialist referral: Consider allergy/immunology referral for patients failing combination OTC therapy

Drug Interaction Considerations

While Loratadine has a favorable safety profile, clinically relevant interactions include:

• CYP3A4 inhibitors (Erythromycin, Ketoconazole, Itraconazole, Clarithromycin): Increase Loratadine plasma concentrations. Clinical significance is generally low due to the drug's wide therapeutic window, but monitor for increased side effects
• CYP2D6 inhibitors (Fluoxetine, Paroxetine): May modestly increase Loratadine levels
• Cimetidine: Increases Loratadine levels by inhibiting hepatic metabolism
• P-glycoprotein substrates: Use caution with narrow therapeutic index P-gp substrates

For a comprehensive review, see our clinical article on Claritin drug interactions.

The Availability Picture: What Your Patients Are Experiencing

Patients may report difficulty finding Claritin for several reasons that are worth understanding in clinical context:

• Peak season demand: Retail locations in high-pollen regions frequently sell out during allergy peaks. Patients may visit 2–3 stores before finding stock.
• Formulation preferences: Patients seeking specific formulations (RediTabs, Liqui-Gels, Children's syrup) may face more limited availability than those willing to accept standard tablets.
• Brand vs. generic confusion: Some patients don't realize generic Loratadine is therapeutically equivalent to brand-name Claritin. Educating patients about generics can significantly improve their ability to find medication.
• Claritin-D access: Products containing Pseudoephedrine (Claritin-D) are kept behind the pharmacy counter and subject to purchase quantity limits, which some patients may interpret as a shortage.

Cost and Access Considerations

As an OTC medication, Loratadine presents unique cost and access considerations for your patients:

• Insurance coverage: Most insurance plans do not cover OTC medications. Patients accustomed to prescription copays may face sticker shock when purchasing OTC Claritin.
• Price range: Brand-name Claritin costs $25–$45 for 30 tablets. Generic Loratadine costs $4–$22 at retail, or as low as $2–$5 with free discount cards (GoodRx, SingleCare).
• HSA/FSA eligibility: OTC Loratadine is eligible for HSA and FSA reimbursement, which some patients may not realize.
• Bulk purchasing: Warehouse stores sell 365-count generic Loratadine for approximately $12–$15, an option worth mentioning to patients on long-term therapy.
• Medicaid: Some state Medicaid programs cover OTC Loratadine — check your state's formulary.

Tools and Resources for Your Practice

Several resources can help you and your patients navigate medication availability and affordability:

• Medfinder for Providers: A free tool that helps patients check pharmacy stock for Claritin and Loratadine in their area. Consider recommending this to patients who report difficulty finding their medication.
• Discount card programs: GoodRx, SingleCare, and RxSaver offer free coupons that can reduce the cost of generic Loratadine to $2–$5 for a 30-day supply.
• Patient education materials: Direct patients to reputable resources about generic equivalence and OTC allergy management options.
• FDA Drug Shortage Database: For real-time shortage monitoring across your formulary, bookmark the FDA shortage site.

Looking Ahead: Allergy Management Trends

Several trends are shaping the allergy management landscape in 2026:

• Extended allergy seasons: Climate data continues to show longer pollen seasons with higher pollen counts, increasing demand for antihistamines and driving more patients to seek care.
• Telehealth integration: Virtual consultations for allergy management continue to grow, making it easier for patients to access specialist recommendations without long wait times.
• Biologics for refractory cases: For patients with severe allergic rhinitis unresponsive to antihistamines and nasal corticosteroids, biologic therapies like Omalizumab continue to expand their evidence base.
• Store-brand proliferation: The increasing availability of store-brand Loratadine helps ensure patients can almost always find a generic option, even when specific brands are temporarily unavailable.

Final Thoughts

Loratadine (Claritin) remains readily available in 2026 with no formal shortage. When patients report difficulty finding it, the issue is almost always localized and demand-driven. Providers can best serve their patients by educating them about generic equivalence, directing them to availability tools like Medfinder, and ensuring prescribing decisions account for the unique cost dynamics of OTC medications.

For additional clinical resources, see our provider guide on how to help patients find Claritin in stock.